Barclays
CUE icon

Barclays’s Cue Biopharma CUE Stock Holding History

Barclays’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.39K Hold
201
– – ﹤0.01% 4885
2025
Q4 		$1.84K Hold
201
– – ﹤0.01% 5058
2025
Q3 		$4.33K Hold
201
– – ﹤0.01% 5094
2025
Q2 		$4.11K Hold
201
– – ﹤0.01% 4988
2025
Q1 		$5.49K Hold
201
– – ﹤0.01% 4929
2024
Q4 		$6.57K Hold
201
– – ﹤0.01% 5037
2024
Q3 		$4.57K Sell
201
-409
-67% -$8.86K ﹤0.01% 5040
2024
Q2 		$22.7K Sell
610
-437
-42% -$21.6K ﹤0.01% 4421
2024
Q1 		$59.4K Sell
1,047
-804
-43% -$56.7K ﹤0.01% 4578
2023
Q4 		$147K Buy
1,851
+1,451
+363% +$104K ﹤0.01% 4535
2023
Q3 		$27.6K Sell
400
-32
-7% -$3.12K ﹤0.01% 4084
2023
Q2 		$47.3K Buy
432
+231
+115% +$27.1K ﹤0.01% 3861
2023
Q1 		$21.5K Hold
201
– – ﹤0.01% 4643
2022
Q4 		$17.2K Sell
201
-5
-2% -$457 ﹤0.01% 4837
2022
Q3 		$14K Sell
206
-34
-14% -$2.92K ﹤0.01% 4180
2022
Q2 		$18K Sell
240
-167
-41% -$19.5K ﹤0.01% 4442
2022
Q1 		$60K Sell
407
-1,074
-73% -$228K ﹤0.01% 4038
2021
Q4 		$503K Buy
1,481
+821
+124% +$317K ﹤0.01% 3202
2021
Q3 		$288K Buy
660
+472
+251% +$165K ﹤0.01% 3439
2021
Q2 		$66K Sell
188
-636
-77% -$247K ﹤0.01% 4008
2021
Q1 		$302K Buy
824
+379
+85% +$156K ﹤0.01% 3493
2020
Q4 		$166K Sell
445
-189
-30% -$75.5K ﹤0.01% 3871
2020
Q3 		$286K Buy
634
+116
+22% +$66.8K ﹤0.01% 3611
2020
Q2 		$381K Buy
518
+296
+133% +$214K ﹤0.01% 3561
2020
Q1 		$94K Sell
222
-443
-67% -$215K ﹤0.01% 4846
2019
Q4 		$317K Buy
665
+190
+40% +$59.7K ﹤0.01% 4678
2019
Q3 		$120K Buy
475
+87
+22% +$20.9K ﹤0.01% 5341
2019
Q2 		$105K Buy
388
+217
+127% +$54K ﹤0.01% 5652
2019
Q1 		$40K Buy
+171
New +$32.5K ﹤0.01% 6025
2018
Q4 		– Sell
-221
Closed -$60K – 6993
2018
Q3 		$60K Buy
221
+178
+414% +$51.4K ﹤0.01% 5957
2018
Q2 		$15K Sell
43
-18
-30% -$7.16K ﹤0.01% 6330
2018
Q1 		$26K Buy
+61
New +$27.8K ﹤0.01% 6313

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
GWMR
GC Wealth Management RIA Cambridge, Massachusetts $1.73B AUM 16.14% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $1.84B AUM 19.34% 1-Year Est. Return

Barclays's CUE Position: Q1 2026 in Review

Barclays held its Cue Biopharma (CUE) position steady in Q1 2026 at 201 shares worth $1.39K. The position accounts for ﹤0.01% of the portfolio, ranked #4885.

Barclays first reported a position in CUE in Q1 2018 and has held it in 32 quarters since. The position peaked at $503K in Q4 2021. 55 funds tracked by Wall St. Rank hold CUE as of Q1 2026.

  • Barclays held 201 shares of Cue Biopharma worth $1.39K as of Q1 2026.
  • Barclays left its Cue Biopharma share count unchanged in Q1 2026.
  • Cue Biopharma made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4885 holding.
  • Barclays first reported a position in Cue Biopharma in Q1 2018 and has held it in 32 quarters since.
  • Barclays's Cue Biopharma position peaked at $503K in Q4 2021.
  • 55 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.